Directory Category: Drug Discovery

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical
company focused on the advancement of immunology based therapies for
prevalent inflammatory conditions, announced today that its AP-014 Phase
I inhaled Ampion clinical study in COVID-19 patients is proceeding to
full open enrollment following clearance by the Safety Monitoring
Committee (SMC), which found Ampion to be safe and well-tolerated after
reviewing results from the first three treatment groups.

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical
company focused on the advancement of immunology based therapies for
prevalent inflammatory conditions, announced today that its AP-014 Phase
I inhaled Ampion™ clinical study in COVID-19 patients is proceeding to
full open enrollment following clearance by the Safety Monitoring
Committee (SMC).